Definition · Plain-language
Fast track designation
Fast Track Designation is an FDA process designed to expedite the development and review of drugs that treat serious conditions and fill an unmet medical need.
The step most authors miss
Doing CRediT right? Don’t stop at the statement.
A CRediT statement credits you inside one paper. The recognition CRediT was built for happens when those roles are tied to you, persistently. Sign in with your ORCID — free — and claim your CRediT contributions on casrai.org, the home of the standard. They become a verified, portable part of your identity, not a line that disappears into one PDF.
Free: claim your contributions, then export a journal-ready CRediT statement, schema.org structured data, JATS XML, CSV or BibTeX — and preview your public profile. A membership publishes that profile publicly and verifies the journals you serve.
What qualifies for Fast Track
Fast Track applies to a drug intended to treat a serious or life-threatening condition where it demonstrates the potential to address an unmet medical need — for example by treating a condition with no available therapy, or improving on existing options. Whether a condition is "serious" is judged by its impact on day-to-day functioning and survival if untreated. A sponsor can request Fast Track at any time during development, and the supporting evidence can be non-clinical or mechanistic, which makes the bar lower than for Breakthrough Therapy.
What the designation provides
A drug with Fast Track Designation benefits from more frequent meetings and written communication with the FDA to discuss the development plan and trial design. It is eligible for rolling review, allowing the sponsor to submit completed sections of a marketing application for review as they are finished rather than waiting to file the entire application at once. Fast Track drugs may also be eligible, if relevant criteria are met, for Accelerated Approval and Priority Review, helping to compress the overall timeline.
Where it fits
Fast Track is one of the FDA’s four expedited programmes for serious conditions, sitting alongside Breakthrough Therapy, Accelerated Approval and Priority Review. It tends to be the broadest entry point because it can rest on the potential to address an unmet need rather than on preliminary clinical evidence of substantial improvement. As with the other programmes, Fast Track changes the process, not the ultimate standard: the drug must still be shown safe and effective for approval.
Key facts
At a glance
- Definition: FDA programme to expedite development of drugs for serious conditions.
- Criteria: Serious condition plus potential to address an unmet medical need.
- Evidence: Can rest on non-clinical or mechanistic data.
- Benefits: More FDA contact, rolling review, possible Priority Review.
- Related programmes: Breakthrough Therapy, Accelerated Approval, Priority Review.
- Not an approval: It expedites the process, not the approval standard.
Common misconceptions
What people often get wrong
Often heard: Fast Track Designation guarantees the drug will be approved quickly.
Actually: Fast Track facilitates development and review but does not guarantee approval. The drug must still meet the FDA’s standard of safety and effectiveness, and approval is never assured by the designation.
Often heard: Fast Track and Accelerated Approval are the same thing.
Actually: They are distinct. Fast Track is a development-and-review designation based on unmet need, while Accelerated Approval is an approval pathway that allows reliance on a surrogate endpoint with required confirmatory trials.
Often heard: Fast Track requires preliminary clinical evidence of a major advantage.
Actually: Fast Track can rest on the potential to address an unmet need, supported by non-clinical or mechanistic data. The requirement for preliminary clinical evidence of substantial improvement applies to Breakthrough Therapy.
